Paid Clinical Trials in District of Columbia

District of Columbia has 838 paid clinical trials enrolling now across cities including Washington D.C., Georgetown and Multiple Locations. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 31, 2026.

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

756 clinical trials

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

for Proteinuric Kidney Disease

Drug: MZE829

Sites in Washington D.C. +67 more locations

Sponsor: Maze Therapeutics

Sex: All·Age: 18 - 68

Code: NCT06830629·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

for Chronic Kidney Disease and Hypertension

Drug: Dapagliflozin

Sites in Washington D.C. +116 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06742723·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

for Malignant Peripheral Nerve Sheath Tumor (MPNST)

Sites in Washington D.C. +1 more location

Sponsor: AeRang Kim

Sex: All·Age: 18+

Code: NCT06735820·Phase 1, Phase 2·Recruiting·Listed Dec 2024

Apply to this trial

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

for Endometrial Carcinoma

Sites in Washington D.C. +326 more locations

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05256225·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

for Transthyretin Amyloidosis

Sites in Washington D.C. +29 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06465810·Recruiting·Listed Jun 2024

Apply to this trial

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

for Viral Lung Infection and Acute Respiratory Failure

Sites in Washington D.C. +34 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT05624450·Phase 3·Recruiting·Listed Nov 2022

Apply to this trial

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

for Systemic Lupus Erythematosus

Sites in Washington D.C. +19 more locations

Sponsor: AstraZeneca

Sex: All·Age: 5 - 17

Code: NCT05835310·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

for Metastatic Colorectal Cancer

Sites in Washington D.C. +10 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06792695·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

for Graves' Disease

Drug: IMVT-1402

Sites in Washington D.C. +57 more locations

Sponsor: Immunovant Sciences GmbH

Sex: All·Age: 18 - 75

Code: NCT06727604·Phase 2·Recruiting·Listed Dec 2024

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

Sites in Washington D.C. +60 more locations

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06496178·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

for Biliary Tract Cancer

Drug: Rilvegostomig

Sites in Washington D.C. +30 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18 - 99

Code: NCT06467357·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

for Locally Advanced Head and Neck Squamous Cell Carcinoma

Sites in Washington D.C. +50 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06129864·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

for Acute Coronary Syndrome

Sites in Washington D.C. +147 more locations

Sponsor: DalCor Pharmaceuticals

Sex: All·Age: 45+

Code: NCT05918861·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

for Non-Small Cell Lung Cancer

Drug: Durvalumab

Sites in Washington D.C. +22 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT05211895·Phase 3·Recruiting·Listed Jan 2022

Apply to this trial

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

for Solid Tumor, Adult

Sites in Washington D.C. +8 more locations

Sponsor: DualityBio Inc.

Sex: All·Age: 18+

Code: NCT06554795·Phase 1, Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Product Surveillance Registry

for Cardiac Rhythm Disorders

Sites in Washington D.C. +128 more locations

Sponsor: Medtronic

Sex: All·Age: All ages

Code: NCT01524276·Recruiting·Listed Feb 2012

Apply to this trial

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

for Non-obstructive Hypertrophic Cardiomyopathy

Sites in Washington D.C. +21 more locations

Sponsor: Imbria Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT07023614·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

Sites in Washington D.C. +35 more locations

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06525220·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

for Neoplasms, Head and Neck

Drug: Dostarlimab

Sites in Washington D.C. +30 more locations

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06256588·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

for Metastatic Non-small Cell Lung Cancer

Drug: Osimertinib

Sites in Washington D.C. +26 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06417814·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

for Arrhythmia

Sites in Washington D.C. +84 more locations

Sponsor: Medtronic

Sex: All·Age: All ages

Code: NCT00271180·Recruiting·Listed Dec 2005

Apply to this trial

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

for Multiple Myeloma

Drug: Belantamab mafodotin

Sites in Washington D.C. +29 more locations

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06679101·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

for Growth Hormone Deficiency

Sites in Washington D.C. +26 more locations

Sponsor: Ascendis Pharma Endocrinology Division A/S

Sex: All·Age: All ages

Code: NCT05820672·Recruiting·Listed Apr 2023

Apply to this trial

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

for Generalized Myasthenia Gravis

Sites in Washington D.C. +1 more location

Sponsor: Alexion Pharmaceuticals, Inc.

Sex: All·Age: 6 - 17

Code: NCT06607627·Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

for Solid Tumor

Sites in Washington D.C. +16 more locations

Sponsor: Biohaven Therapeutics Ltd.

Sex: All·Age: 18+

Code: NCT06384807·Phase 1, Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

for Acute Ischemic Stroke

Sites in Washington D.C. +16 more locations

Sponsor: Corxel Pharmaceuticals

Sex: All·Age: 18 - 90

Code: NCT06990867·Phase 2, Phase 3·Recruiting·Listed May 2025

Apply to this trial

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

for Acute Respiratory Distress Syndrome

Sites in Washington D.C. +31 more locations

Sponsor: Direct Biologics, LLC

Sex: All·Age: 18 - 75

Code: NCT05354141·Phase 3·Recruiting·Listed Apr 2022

Apply to this trial

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

for Growth Hormone Deficiency

Sites in Washington D.C. +26 more locations

Sponsor: Ascendis Pharma Endocrinology Division A/S

Sex: All·Age: 1 - 18

Code: NCT05775523·Recruiting·Listed Mar 2023

Apply to this trial

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

for Systemic Sclerosis Associated Interstitial Lung Disease

Sites in Washington D.C. +23 more locations

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT05878717·Phase 2, Phase 3·Recruiting·Listed May 2023

Apply to this trial

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

for Atopic Dermatitis

Sites in Washington D.C. +21 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT06947993·Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

for HIV Infections

Sites in Washington D.C. +6 more locations

Sponsor: ViiV Healthcare

Sex: All·Age: 6 - 12

Code: NCT05674656·Phase 1, Phase 2·Recruiting·Listed Jan 2023

Apply to this trial